Development of liquiritigenin-phospholipid complex with the enhanced oral bioavailability.
10.1016/S1875-5364(20)60035-8
- Author:
Chang-Can SHI
1
,
2
;
Kun-Ming QIN
3
;
Ke XU
4
;
An CHEN
4
;
Ting CAI
5
;
Bao-Chang CAI
1
,
6
Author Information
1. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, China
2. School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
3. Nanjing Haichang Chinese Medicine Group Corporation, Nanjing 210061, China.
4. School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
5. School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: tcai@cpu.edu.cn.
6. Nanjing Haichang Chinese Medicine Group Corporation, Nanjing 210061, China.
- Publication Type:Journal Article
- Keywords:
Characterization;
Cioavailability;
Liquiritigenin;
Liquiritigenin-phospholipid complex;
Solubility
- MeSH:
Administration, Oral;
Animals;
Biological Availability;
Flavanones/pharmacokinetics*;
Phospholipids/pharmacokinetics*;
Rats;
Solvents
- From:
Chinese Journal of Natural Medicines (English Ed.)
2020;18(12):916-921
- CountryChina
- Language:English
-
Abstract:
In the present study, liquiritigenin-phospholipid complex (LPC) was developed and evaluated to increase the oral bioavailability of liquiritigenin. A single-factor test methodology was applied to optimize the formulation and process for preparing LPC. The effects of solvent, drug concentration, reaction time, temperature and drug-to-phospholipid ratio on encapsulation efficiency were investigated. LPCs were characterized by UV-visible spectroscopy, differential scanning calorimetry (DSC), fourier transform infrared spectroscopy (FTIR), and powder X-ray diffractometry (PXRD). The apparent solubility and n-octanol/water partition coefficient were tested. The pharmacokinetic characteristics and bioavailability of the LPC were investigated after oral administration in rats in comparison with liquiritigenin alone. An LPC was successfully prepared. The optimum level of various parameters for liquiritigenin-phospholipid complex was obtained at the drug concentration of 8 mg·mL
